2.1
Tenecteplase (Metalyse, Boehringer Ingelheim) is indicated 'in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4.5 hours from last known well and after exclusion of intracranial haemorrhage'.
2 Information about tenecteplase
Anticipated marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for tenecteplase.
Price
2.3
The list price of a 25 mg vial of tenecteplase is £602.70 (excluding VAT; company submission).
2.4
Costs may vary in different settings because of negotiated procurement discounts.